omniture
logo
Search
江苏先声药业有限公司 SIMCERE PHARMACEUTICAL GROUP
Media Room

Latest News

rss

Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day

NANJING, China, April 19, 2022 /PRNewswire/ -- On April 15, 2022, Simcere Pharmaceutical (2096.HK),...

2022-04-19 10:28 2012

SIMCERE PHARMA (HK.2096) to host 2022 R&D Day

HONG KONG, April 7, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pha...

2022-04-07 21:39 2564
SIMCERE PHARMA (HK.2096) to host 2022 R&D Day

Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer

HONG KONG, Feb. 24, 2022 /PRNewswire/ -- On February 23 2022, Simcere Pharmaceutical Group (2096.HK...

2022-02-24 13:34 1662

Simcere Pharma (2096.HK) Announces a Positive Profit Alert

HONG KONG, Feb. 23, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (the "Company", toget...

2022-02-23 16:22 3134

Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals

NANJING, China, Feb. 7, 2022 /PRNewswire/ -- Simcere is thrilled to announce Bijoyesh Mookerjee, M....

2022-02-08 10:01 1879
Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals

Simcere and Shanghai Institute of Materia Medica Enter a Collaboration to Jointly Develop Next-Gen COVID-19 Oral Antiviral Treatments

NANJING, China, Nov. 22, 2021 /PRNewswire/ -- On November 17, 2021, Simcere Pharmaceutical Group Li...

2021-11-23 11:22 1998
12